Humacyte, Inc. (NASDAQ:HUMA) Short Interest Up 14.4% in September

Humacyte, Inc. (NASDAQ:HUMA) was the recipient of a significant increase in short interest in the month of September. As of September 30th, there was short interest totalling 16,030,000 shares, an increase of 14.4% from the September 15th total of 14,010,000 shares. Based on an average daily volume of 3,130,000 shares, the short-interest ratio is presently 5.1 days. Currently, 16.4% of the company’s stock are short sold.

Humacyte Price Performance

Humacyte stock traded up $0.11 during trading hours on Wednesday, hitting $5.81. The stock had a trading volume of 3,740,722 shares, compared to its average volume of 2,260,759. Humacyte has a 1-year low of $1.96 and a 1-year high of $9.97. The stock has a market capitalization of $691.88 million, a price-to-earnings ratio of -5.81 and a beta of 1.45. The stock’s fifty day moving average is $5.90 and its two-hundred day moving average is $5.88. The company has a debt-to-equity ratio of 0.61, a current ratio of 5.41 and a quick ratio of 5.41.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). As a group, analysts predict that Humacyte will post -1.09 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

HUMA has been the topic of a number of analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $13.00 price objective on shares of Humacyte in a report on Friday, September 20th. Benchmark reaffirmed a “buy” rating and set a $15.00 price target on shares of Humacyte in a research note on Thursday, October 10th. BTIG Research raised their price objective on shares of Humacyte from $8.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, July 15th. Finally, EF Hutton Acquisition Co. I upgraded shares of Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Humacyte has a consensus rating of “Buy” and a consensus price target of $9.80.

Insider Activity at Humacyte

In related news, Director Brady W. Dougan sold 252,676 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $6.71, for a total value of $1,695,455.96. Following the sale, the director now owns 4,306,464 shares of the company’s stock, valued at $28,896,373.44. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Brady W. Dougan sold 252,676 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $6.71, for a total transaction of $1,695,455.96. Following the transaction, the director now directly owns 4,306,464 shares in the company, valued at approximately $28,896,373.44. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Kathleen Sebelius sold 5,182 shares of Humacyte stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $5.40, for a total value of $27,982.80. Following the completion of the transaction, the director now owns 40,276 shares in the company, valued at $217,490.40. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,084,153 shares of company stock worth $6,869,996. Company insiders own 23.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in Humacyte by 28.7% in the 1st quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company’s stock valued at $12,501,000 after purchasing an additional 896,415 shares during the last quarter. Millennium Management LLC increased its holdings in shares of Humacyte by 504.3% during the 2nd quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock worth $7,677,000 after buying an additional 1,334,641 shares during the last quarter. Renaissance Technologies LLC increased its stake in Humacyte by 693.0% during the second quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock worth $2,881,000 after acquiring an additional 524,600 shares during the last quarter. Marshall Wace LLP raised its holdings in shares of Humacyte by 3,301.5% in the 2nd quarter. Marshall Wace LLP now owns 463,662 shares of the company’s stock worth $2,226,000 after purchasing an additional 450,031 shares during the period. Finally, Private Advisor Group LLC lifted its stake in shares of Humacyte by 15.4% in the 2nd quarter. Private Advisor Group LLC now owns 366,600 shares of the company’s stock valued at $1,760,000 after purchasing an additional 48,976 shares in the last quarter. 44.71% of the stock is currently owned by institutional investors and hedge funds.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.